Discussion
CFTR modulators, a class of medications that boost the activity of a faulty CFTR protein in people with cystic fibrosis (CF), do not appear to increase the overall risk of depression, anxiety, or other neuropsychiatric symptoms in people with the genetic disorder, a U.S. study has found. The findings…
